2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. N-myristoyltransferase
  5. N-myristoyltransferase Inhibitor

N-myristoyltransferase Inhibitor

N-myristoyltransferase Inhibitors (10):

Cat. No. Product Name Effect Purity
  • HY-147308
    Zelenirstat
    		Inhibitor 99.76%
    Zelenirstat is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. Zelenirstat can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma.
  • HY-164285
    MYX1715
    		Inhibitor 99.55%
    MYX1715 is an inhibitor of N-Myristoyltransferase (NMT) with a KD value of 0.09 nM. MYX1715 inhibits the proliferation of LU0884 and LU2511 with IC50 values of 44 nM and 9 nM. MYX1715 exhibits antitumor efficacy against neuroblastoma and gastric cancer in mouse models. MYX1715 can be used as ADC toxin.
  • HY-160945
    NMT-IN-7
    		Inhibitor 98.83%
    NMT-IN-7 is a N-myristoyl transferase (NMT) inhibitor, with IC50s of 2.1 nM for HsNMT1M, 0.6 nM for SU-DHL-10 cell. NMT-IN-7 can be used as a ADC cytotoxin.
  • HY-171814
    Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)-NMT-IN-7
    		Inhibitor
    Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)-NMT-IN-7 (Compound DC-2) is a drug-linker conjugate for ADC. Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)-NMT-IN-7 consists of a NMT inhibitor (HY-160945) and a stable and cleavable linker (Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)). Mal-PEG2-amide-C2-amide-Phenyl(β-D-glucuronide)-NMT-IN-7 can be used for synthesis of ADCs.
  • HY-134199
    IMP-1002
    		Inhibitor
    IMP-1002 is a Plasmodium N-myristoyltransferase (NMT) inhibitor. IMP-1002 inhibits myristoylation activity, blocks parasite development. IMP-1002 can be used for the research of malaria.
  • HY-183263
    MYX1715 analog 1
    		Inhibitor
    MYX1715 analog 1 is an analog of MYX1715 (HY-164285). MYX1715 analog 1 is an N-myristoyltransferase (NMT) inhibitor that inhibits protein myristoylation modification. MYX1715 analog 1 can be conjugated to targeting antibodies via cleavable or non-cleavable linkers for use as an ADC cytotoxin. MYX1715 analog 1 is used in the development of drugs targeting tumor-associated antigens.
  • HY-136625
    LY134046
    		Inhibitor
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT) with cardiovascular activity. LY134046 causes sustained reductions in mean arterial blood pressure and heart rate, but no significant reductions in norepinephrine concentrations in the rat brain. LY134046 does not interact with adrenergic or cholinergic receptors, and its hypotensive and bradycardic effects do not require neurogenic tension. LY134046 (40 mg/kg/day) causes sustained and significant inhibition of hypothalamic and brainstem NMT activity, resulting in central norepinephrine depletion.
  • HY-E70394
    S-Acetonyl-CoA
    		Inhibitor
    S-Acetonyl-CoA (Acetonyl-coenzyme A) is a non-reactive structural analog of acetyl-CoA that acts as a competitive inhibitor against multiple target enzymes. S-Acetonyl-CoA lacks the characteristic thioester group of acetyl-CoA, retaining only a thioether structure. S-Acetonyl-CoA competes with acetyl-CoA for binding to citrate synthase, phosphate transacetylase, carnitine acetyltransferase, and N-myristoyltransferase 1. S-Acetonyl-CoA serves as a reagent for investigating acetyl-CoA-dependent physiological processes.
  • HY-171788
    NMT-IN-8
    		Inhibitor
    NMT-IN-8 (Compound Ex.129) is an orally active and highly selective inhibitor of N-myristoyl transferase (NMT) with an IC50 value of ＜10 nM. NMT-IN-8 binds to the peptide binding pocket of NMT, blocking its catalyzed protein N-myristoylation to interfere with key pathways such as protein trafficking, signal transduction, and viral replication. NMT-IN-8 is promising for research of oncology (e.g., MYC-addicted cancers, B-cell lymphoma) and infectious diseases (e.g., malaria, HIV, rhinovirus infection).
  • HY-183872
    FTR1335
    		Inhibitor
    FTR1335 is an Antifungal agent as well as a selective, substrate peptide-competitive, and myristoyl-CoA non-competitive inhibitor of N-myristoyltransferase CaNmt, with an IC50 of 0.49 nM against Candida albicans CaNmt. FTR1335 exhibits fungicidal activity against Candida albicans and inhibits the growth of Candida tropicalis. FTR1335 can be used in research related to Candida albicans infections.